Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04654104 | Immune Checkpoints in COPD(CP-COPD) | unknown | — | 80 | University of CatanzaroOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603013 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | unknown | Phase 2 | 45 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04923412 | Vagus Nerve Preservation and Chronic Cough in Non-small Cell Lung Cancer Surgery | unknown | N/A | 214 | Seoul National University Bundang HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05586035 | Analysis of Factors and Treatment Related to Chronic Cough After Pulmonary Resection | unknown | — | 300 | Guangdong Provincial People's HospitalOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05587114 | Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood | unknown | — | 150 | Korea University Guro HospitalOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05583916 | Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery(VALUE) | unknown | N/A | 20 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT03317080 | Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer(LUNGCA) | unknown | — | 400 | West China HospitalOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05583409 | SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC | unknown | N/A | 72 | Li ZhangOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05577052 | SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases | unknown | N/A | 100 | Wuhan UniversityOTHER | 0 | Oct 13, 2022 | clinicaltrials |
| NCT05574998 | First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial(FTANLCNDG) | unknown | Phase 2 | 100 | Qianfoshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05565677 | Prognostic Value of Lung Cancer MicroAnatomy in 3D(LungCaMa3D) | unknown | — | 50 | Aristotle University Of ThessalonikiOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT05547737 | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer(NSCLC) | unknown | — | 500 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05548348 | First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation | unknown | Phase 2 | 30 | Chongqing University Cancer HospitalOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05542992 | Deep Learning Model for Pure Solid Nodules Classification | unknown | — | 260 | Chang ChenOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04455438 | SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions(STRILL) | unknown | N/A | 15 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05534113 | Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC | unknown | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05532527 | Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study(NSCLC) | unknown | N/A | 35 | Henan Provincial People's HospitalOTHER | 0 | Sep 8, 2022 | clinicaltrials |
| NCT05529355 | Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 45 | Anhui Chest HospitalOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05513664 | Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer | unknown | — | 80 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05416775 | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 168 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507606 | Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04122833 | Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study | unknown | — | 80 | Konkuk University Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05380024 | A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 10 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | unknown | Phase 2 | 42 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05497544 | ORE - 30 Seconds (Oncologists Recommend Exercise in 30 Secs)(ORE) | unknown | N/A | 60 | Universita di VeronaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05117658 | Study of HA121-28 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 83 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05486988 | ctDNA as a Biomarker for Treatment in Advanced NSCLC | unknown | — | 500 | Fuzhou General HospitalOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05136300 | Pulmonary Rehabilitation After Minimal Invasive Surgery in Lung Cancer(PROMISE) | unknown | N/A | 100 | IsalaOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05485350 | Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 32 | Peking University Third HospitalOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05430009 | Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | unknown | Phase 1 | 12 | VA Ann Arbor Healthcare SystemFED | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04197076 | Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB | unknown | — | 200 | Shanghai Chest HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04366219 | Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer(CBP-COVID) | unknown | — | 2,000 | Centre Hospitalier le MansOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05477615 | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | unknown | Phase 2 | 28 | Jin Hyoung KangOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05453812 | Meaning of Recovery After Lung Cancer Surgery | unknown | — | 111 | Seoul National University HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03971175 | Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC(PROFILER) | unknown | N/A | 540 | University Hospital TuebingenOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2022source: clinicaltrials